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Background: The role of vitamin D in management of depression is unclear. Results from observational and emerging
randomized controlled trials (RCTs) investigating the efficacy of vitamin D in depression lack consistency - with some
suggesting a positive association while others show a negative or inconclusive association.
Methods/Design: The primary aim of this study is to conduct a systematic review of RCTs to assess the effect of oral
vitamin D supplementation versus placebo on depression symptoms measured by scales and the proportion of patients
with symptomatic improvement according to the authors’ original definition. Secondary aims include assessing the
change in quality of life, adverse events and treatment discontinuation. We will conduct the systematic review and
meta-analysis according to the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions.
We will search the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (1966 to present), EMBASE
(1980 to present), CINAHL (1982 to present), PsychINFO (1967 to present) and ClinicalTrials.gov. Unpublished work will
be identified by searching two major conferences: the International Vitamin Conference, the Anxiety Disorders and
Depression Conference, while grey literature will be acquired by contacting authors of included studies. We will use
the random-effects meta-analysis to synthesize the data by pooling the results of included studies.
Discussion: The results of this systematic review will be helpful in clarifying the efficacy of vitamin D
supplementation and providing evidence to establish guidelines for implementation of vitamin D for depression in
general practice and other relevant settings.
Study registration: Unique identifier: CRD42013003849.
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Depression is characterized by a depressed mood or loss
of interest or pleasure in almost all daily activities for a
period of at least two weeks [1]. Depression is the fourth
leading cause of an increase in disability-adjusted life-
years (DALY) worldwide [2], and it is projected to be the
second leading cause of burden of disease by 2030 after
human immunodeficiency virus (HIV) and Acquired Im-
mune Deficiency Syndrome (AIDS) [3].
The Diagnostic and Statistical Manual of Mental Dis-
orders (DSM) IV has well-defined operational criteria for* Correspondence: thabanl@mcmaster.ca
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reproduction in any medium, provided the ordiagnosing depressive disorders for trained clinicians.
However many other screening and research diagnostic
tools are also available, including the Feighner Criteria
[4], Research Diagnostic Criteria [5], self-rating question-
naires (such as Beck Depression Inventory (BDI) [6,7],
Center for Epidemiologic Studies Depression scale (CES-D)
[8], General Health Questionnaire (GHQ) [9], etcetera)
and clinician-rating scales (such as Hamilton Depression
Rating Scale (HAM-D) [10,11], Montgomery-Åsberg De-
pression Rating Scale (MADRS) [12], Inventory for De-
pressive Symptomatology-Clinician Rated or Self-rated
(IDS-C/SR) [13], etcetera). Clinical practice guidelines for
the treatment of depression recommend the use of antide-
pressants, cognitive-behavior therapy, and interpersonal
psychotherapy [14]. Nevertheless, patients are prone to
fail to receive optimal treatment due to its poor publichis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ment. More simple and acceptable interventions are ur-
gently needed.
Vitamin D is produced endogenously in the skin by
sun exposure, and humans also obtain vitamin D from
the diet and from supplements to a minor extent. The
recommended intake of vitamin D varies from 200 inter-
national units (IU) to 1000 IU per day [16]. Vitamin D
supplementation increases serum 25-hydroxy vitamin D
(25(OH)D) levels, thereby potentially correcting the
effects of vitamin D deficiency [16]. Both vitamin D2
(ergocalciferol) and vitamin D3 (cholecalciferol) are avail-
able as supplementations to maintain serum 25(OH)D
concentrations. However, since vitamin D3 is considered
to be more potent than vitamin D2 [17,18], vitamin D3
supplementation has been widely used with different
doses in trials related to depression [19-22].
It is commonly known that vitamin D is essential for
the maintenance of calcium homeostasis and for bone
health [16], but its role in the brain is not fully under-
stood. Because the receptor of vitamin D is found in
areas of the brain that are involved in the development of
depression [23], vitamin D and its relationship to depres-
sive symptoms and other psychiatric disorders are under
investigation [24,25]. Treatment of depression with vita-
min D has potentially profound implications, because for
patients in whom vitamin D is an effective antidepres-
sant, it will be one of the most cost-effective treatments
in psychiatry, and one with negligible side effects [26].
A number of observational studies have investigated
the relationship between depression and vitamin D with
conflicting results. While cross-sectional studies identified
an association between low level of serum 25(OH)D and
scores on measures of depression inconclusively [27-30],
some prospective studies [31-33] using large samples
reported a significant association. However, it is difficult
to corroborate the causality in observational research due
to the numerous potential confounders including age,
time spent outdoors, latitude, physical activity, body mass
index, smoking, alcohol use, etcetera [34]. Emerging ran-
domized controlled trials (RCTs) of vitamin D supple-
mentation have been reported, but their findings were
also inconsistent. For instance, Jorde et al. [35] found an
effect of high dose vitamin D supplementation on de-
pressive symptoms, whereas other research failed to ob-
serve a significant treatment effect [20,36]. Therefore, it
is essential to summarize the best available evidence to
date to clarify the efficacy of vitamin D.
A recent systematic review investigating the relation-
ship between vitamin D deficiency and depression in
adults presented significant positive associations in ob-
servational studies [37]. Nevertheless, it did not include
any RCT up to February 2011 according to the authors’
criterion, thereby failing to assess the efficacy of vitamin Dsupplementation in depression in trials. Plenty of RCTs on
vitamin D and depression have been published since then.
Thus, to identify the efficacy of vitamin D supplementation
in depression in adults with depressive symptoms/diagno-
sis or at risk of depression, we will conduct a comprehen-
sive systematic review and meta-analysis of RCTs.
Aims
The overall purpose of this systematic review is to evalu-
ate the efficacy of oral vitamin D supplementation in de-
pression in adults with depressive symptoms/diagnosis
or at risk of depression in RCTs. The primary aim is to
assess the effect of oral vitamin D supplementation ver-
sus placebo on depression symptoms measured by scales
(for continuous outcome) and the proportion of patients
with symptomatic improvement according to the authors’
original definition (for dichotomous outcome). Secondary
aims include assessing the change in quality of life, adverse
events and treatment discontinuation.
Methods/Design
Criteria for considering studies for this review
Type of studies
We will include only RCTs investigating the effect of
oral vitamin D supplementation on depression in adults
(18 years of age and over). Only conventional parallel
designs will be eligible, while cross-over RCTs will be ex-
cluded because depressive symptoms may not be static
and participants’ variability is hard to interpret.
Type of participants
We will include adults who are at risk of depression, have
depressive symptoms, or have a primary diagnosis of de-
pression based on the authors’ definition. Risk factors for
depression in our study are manipulated as: having a
family history of depression [38], obesity for adults [39],
postpartum period for women [40], perimenopause for
women in midlife [41], bereavement, sleep disturbance,
disability, prior depression and female gender for the eld-
erly [42]. Subjects with a diagnosed depressive disorder
or with depressive symptoms that are secondary to another
medical condition will be included, but trials in which the
primary focus is another major psychiatric condition such
as anxiety disorders, will be excluded. Studies involving
participants with vitamin D abnormalities such as hyper-
parathyroidism, will also be excluded. If the same partici-
pants are assessed in different time points or in multiple
studies, we will extract and analyze all the data of different
follow-up periods, and choose those with the largest sam-
ple size of the same follow-up period for analysis.
Type of interventions
At least one of the intervention arms has to include oral
intake of vitamin D as a mono-intervention. We will
Table 1 MEDLINE search terms
Outcome Descriptor































Search for randomized controlled trials 32. trial
33. clinical trial







Search for combinations 41. 24 AND 31 AND 40
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mentation. Studies that combined vitamin D with any
other vitamin, antidepressant, calcium, or light therapy
will be excluded, because we want to isolate the interven-
tion effect due to vitamin D and obtain its efficacy by dir-
ect comparison with placebo.
Comparison
Only trials using placebos in their control groups will be
included. Specifically, the comparison will be oral vita-
min D supplementation versus placebo.
Type of outcome measures
Primary outcome Our primary outcome is the effect of
oral vitamin D supplementation on improvement in the
depression symptoms measured by depression symptoms
scales (continuous outcome) and the proportion of patients
with symptomatic improvement according to the authors’
definition (dichotomous outcome), compared to placebo. If
the original authors report outcomes using several different
scales corresponding with our definition of response, we
will give preference to BDI for self-rating questionnaires
and HAM-D for observer-rating scales.
Secondary outcome Secondary outcomes include:
1. change in quality of life;




We will search the Cochrane Central Register of Con-
trolled Trials (CENTRAL), MEDLINE (1966 to present),
EMBASE (1980 to present), CINAHL (1982 to present),
PsychINFO (1967 to present) and ClinicalTrials.gov ex-
haustively and comprehensively. In our searches, we will
use descriptors that include synonyms for depression, vita-
min D and randomized controlled trials in various combi-
nations, for example, 'vitamin D or 25 hydroxyvitamin D'
and 'depression or mood disorder' and 'RCT or clinical
trial'. We will first search MEDLINE (see Table 1). Subse-
quent search strategies will be derived from the MEDLINE
strategy and adapted for each database. Our searches will
not be limited by language, publication status or setting.
Reference lists
The reference lists of articles and other reviews retrieved
in the search or known to the authors will be searched
for relevant articles.
Conference abstracts
Unpublished work will be identified by searching the ab-
stract books or websites of two major conferences: theInternational Vitamin Conference, the Anxiety Disorders
and Depression Conference. Any abstract of interest will
be assessed for further detail by contacting the authors.
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We will try to contact authors of included studies to
acquire other data that may either be unpublished or
informally published or ongoing and which is related to
efficacy of vitamin D in depression.
Data collection and analysis
A summary of the identification, screening and inclusion
of studies in this review will be presented as a PRISMA
(Preferred Reporting Items for Systematic Reviews and
Meta-analyses) diagram [43].
Selection of studies
Two review authors (GL and SZ) will independently
screen and select studies for possible inclusion in the study.
First, the titles and abstracts of trials identified from the
search will be independently reviewed and pooled for fur-
ther screening. Secondly, each review author will inde-
pendently examine the full text of all trials that were
identified from the title and abstract screens. Each reviewer
will compile a list of studies that meet the inclusion cri-
teria. The contents of each review author’s list will be com-
pared, and any disagreement will be resolved by discussion
and consensus between all of the review authors. Agree-
ment between authors will be quantified using the Kappa
statistic [44].
Data extraction and management
Two review authors (GL and SZ) will independently ex-
tract data using specially developed data extraction forms.
Information will be collected on:
1. participant characteristics (age, sex, numbers of
participants, diagnosis or symptoms of depression,
co-morbidity, severity of depression, study setting
including season and latitude where study was
conducted, inclusion and exclusion criteria in the
included studies, baseline serum 25(OH)D and the
assay method, washout periods for antidepressants
and other supplements);
2. intervention details (number of arms, sample size
for each, randomization and allocation
concealment method, blinding, dose and type of
supplementation, duration, withdrawals, and
drop-outs);
3. outcome measures (description of measures used,
continuous/dichotomous nature, results of
intervention including scores of depression and
interim/final serum 25(OH)D, and adverse
outcomes).
We will pilot the data extraction form prior to its use.
Any disagreement will be resolved by discussion and
consensus between all of the review authors.Statistical analysis
A random-effects meta-analysis will be performed through-
out to synthesize the data by pooling the results of the
included studies. Heterogeneity between included studies
will be assessed using both the chi-square test and the I2
statistic [45,46]. In addition, to make the probability
statement for the efficacy of vitamin D and to incorpor-
ate the prior beliefs and external information (that is, ob-
servational data), we will synthesize the results from the
RCTs using a hierarchical Bayesian random-effects model
[47-49] in conjunction with observational studies in-
cluded in a recent systematic review [37]. Specifically, ob-
servational studies investigating relationship between
vitamin D measurements as a risk factor and depression
as the outcome of interest in adults will be eligible for
pooled analysis as prior distributions to conduct Bayesian
meta-analysis.
We will analyze the data using Review Manager (RevMan)
version 5.2 for windows (the Nordic Cochrane Center,
the Cochrane Collaboration, Copenhagen, Denmark). We
will present the results with 95% confidence intervals.
We will calculate the pooled risk ratio (RR) and the
odds ratio (OR) for dichotomous data, the weighted
mean difference (WMD) for continuous data measured
on the same scale, and the standardized mean difference
(SMD) for data measured on different scales [50].
We will use the software WinBUGS 1.4 (MRC Biostatis-
tics Unit, Cambridge, UK) to apply three prior distributions
to the Bayesian random-effects model: a 'non-informative'
or 'vague' prior distribution [51,52], an 'informative' prior
distribution [47,53] and a 'skeptical' prior distribution [52],
the latter two of which will be based on the pooled obser-
vational studies [37]. The efficacy of the intervention will
then be acquired from the posterior distribution of the
Bayesian analysis, presenting as a SMD, or a RR (or OR)
with 95% associated credible interval.
Dealing with missing data
For missing or unclear data, the authors of the studies will
be contacted during eligibility assessment and data abstrac-
tion. Missing data will also be sought from secondary pub-
lications of the same study. However, if data are only
available in graphic format, we will impute approximations
of the mean. If the effort to seek further information from
original authors or secondary studies is fruitless, in order
to estimate standard deviations (SDs) we will borrow SDs
from other trials included in this meta-analysis [54].
Assessment of risk of bias in included studies
We will assess risk of bias for each included study by an
adapted Cochrane Collaboration 'Risk of bias' assess-
ment tool [50], including sequence generation, allocation
concealment, blinding, incomplete outcome data/loss to
follow-up, selective outcome reporting and other issues.
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defined as: yes (criteria applied and described appropri-
ately or acknowledged in the study), no (criteria inappro-
priately applied) and unclear (criteria not described and
impossible to obtain from the study). Each study will
then be classified into one of the categories below.
 High risk of bias: one or more criteria not applied/met.
 Moderate risk of bias: one or more criteria unclear.
 Low risk of bias: all criteria applied/met.
The review authors will discuss any disagreement in
the assessment of risk of bias to reach a consensus.
Assessment of quality of evidence across studies
We will assess the quality of evidence in this systematic
review using the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) tool [55]
with GRADEprofiler (GRADEpro) version 3.6 software,
defining the quality of evidence for each outcome as the
extent to which one can be confident that an estimate of
effect or relation is close to the quantity of specific interest
[50]. The GRADE system rates the quality of evidence
across studies as one of four levels: very low, low, moderate
and high. RCTs are categorized as high quality but can be
downgraded for several reasons, including limitation in
study design, indirectness of evidence, imprecision of re-
sults, unexplained heterogeneity or inconsistency of results,
or high probability of publication bias [55].
Assessment of heterogeneity in included studies
We will first assess clinical heterogeneity by determining
whether the studies are similar enough to pool. In the
event that they are, statistical heterogeneity will be eval-
uated using the I2 statistic, with a value of I2 >50% or
P value <0.1 taken as implying significant heterogen-
eity [45,46]. If statistical heterogeneity is found, it will
be examined by subgroup and sensitivity analyses.
Subgroup analysis
We plan to investigate the heterogeneity by carrying out
the following subgroup analyses:
1. different vitamin D dosages (that is, less than
4,000 IU/day versus more than 4,000 IU/day);
2. different study settings (that is, high versus low
latitude where study was conducted);
3. males versus females;
4. institutional versus community dwellers; and
5. clinical versus general population sample.
Sensitivity analysis
We hypothesize that vitamin D supplementation will be
less effective on depression in studies with a high risk ofbias and in studies with short duration (that is, less than
six months), thus we will carry out sensitivity analyses
by excluding studies classified as having high risk of bias
and removing those having short duration. Also, a fixed-
effects model will be conducted for sensitivity analysis.
Assessment of reporting biases
We will construct a funnel plot to investigate the potential
for publication bias for the primary outcomes relating to
the diagnosis or symptoms of depression, by means of vis-
ual inspection for signs of asymmetry, Begg’s rank correl-
ation and Egger’s regression tests [50] using the STATA
metabias command.
Discussion
The efficacy of vitamin D supplementation in depression
has raised lots of concern. Vitamin D is considered as a
neurosteroid [56], and now it is attested that vitamin D
metabolites can cross the blood–brain barrier [34]. Be-
cause of the widespread presence of vitamin D receptor
in areas of the brain including the hippocampus which is
associated with the development of depression [23], it
could be speculated that there is a clinical effect of vita-
min D on depression.
The initial suggestion that vitamin D may be linked to
depression was based on the relation between low vita-
min D and high prevalence of seasonal affective disorder
in winter at high latitudes [57]. Since then a number of
observational studies had been published, but they
yielded inconclusive results mainly as to whether the
lower levels of vitamin D were a cause or consequence
of depression [26,34]. Also several RCTs had looked at
the efficacy of vitamin D supplements in depression, and
if any, the association between depression and the posi-
tive effect by vitamin D supplementation that may indi-
cate a causative relation. But, the findings of these trials
were not uniform [20,35,36,58]. Divergent results have
been reported in various population, study settings, dur-
ation, etcetera.
A review by Bertone-Johnson concluded that the evi-
dence linking vitamin D to the development of depression
remains largely circumstantial, after analyzing several ob-
servational studies and one RCT [34]. Two other reviews
also demonstrated that it was premature to conclude a sig-
nificant clinical effect of vitamin D supplementation on de-
pression [59,60], while Anglin et al. failed to summarize
the evidence of RCTs [37]. Therefore, a systematic review
based on RCTs will yield a better understanding of the effi-
cacy of vitamin D in depression, which will be helpful in
establishing guidelines for implementation in general prac-
tice and other relevant settings.
To our knowledge, this systematic review and meta-
analysis is the first to evaluate the efficacy of vitamin D
supplementation in depression in RCTs. Summarizing
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will be very useful, because there is a positive public per-
ception of oral vitamin D supplementation, which could
lead to high rates of patient adherence [61]. Further-
more, vitamin D supplementation may be cost-effective
with rare adverse effects [16] in preventing development
of depression or treating depressive symptoms.
We anticipate that the review will provide valuable evi-
dence of beneficial efficacy of vitamin D supplementa-
tion in depression. The review will also probably inform
clinicians and healthcare providers about a simple and
acceptable intervention and method that will serve the
needs of people at risk of depression or with depressive
symptoms, or depression patients.
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